ClinicalTrials.gg
CompletedNCT03830749Updated Feb 28, 2024

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

A Phase 2 interventional study of Eltrombopag in Immune Thrombocytopenia, sponsored by Humanity & Health Medical Group Limited. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Humanity & Health Medical Group Limited · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
17th of 36
53 · median 40
Started
2018
with 2 others
Phase 2
15 of 36
2 open now
Registered
24th of 36
by date
Lead sponsor
1 of 36
Humanity & Health Medical Group Limited

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 17th largest by enrollment, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 24th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Current first line treatments for immune thrombocytopenia (ITP) usually have transient effects and prolonged platelet response rate off therapy remains low. The aim is to evaluate whether a 12-week course of eltrombopag plus pulsed dexamethasone as first line therapy can increase the proportion of patients with prolonged response. Diagnosis of ITP is established according to the American Society of Hematology guidelines. Eligible ITP subjects have platelet counts \<30×109/L or counts \<50×109/L and significant bleeding symptoms (WHO bleeding scale 2 or above). Subjects must have no prior ITP treatment except platelet transfusions. Treatment consists of eltrombopag 25-75 mg daily according to platelet response for 12 weeks plus pulsed dexamethasone, 40 mg daily for 4 consecutive days every 4 weeks for 1-3 courses. The primary endpoint is prolonged response rate which was defined as the proportion of enrolled subjects maintaining platelet counts >50×109/L for more than 6 months without any ITP therapy after completion of 12-week therapy.

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has signed and dated a written .
  2. Adults (≥18 years) diagnosed with ITP according to the American Society for Hematology/British Committee for Standards in Haematology (ASH/BCSH) Guidelines. In addition, the peripheral blood smear should support the diagnosis of ITP with no evidence of other disease causative of thrombocytopenia (e.g., pseudo thrombocytopenia, myelofibrosis). The physical examination should be normal or at least not show signs suggestive of any disease likely to be associated with thrombocytopenia.
  3. No prior ITP treatment except transfusions
  4. Subject has no intercurrent medical event, including evidence of any thrombosis.
  5. Normal (PT/INR) and activated partial thromboplastin time (aPTT), no history of hypercoagulable state.
  6. The following clinical chemistries must be within the normal reference range:

    creatinine, , AST, total , total albumin and alkaline phosphatase.

  7. Subject is practicing an acceptable method of (documented in chart).
  8. Subject is able to understand and comply with protocol requirements and instructions.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality, other than ITP, identified on the screening examination, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another diagnosis.
  2. History of active or on cancer therapy. Patients with a history of malignancy in complete remission for longer than 5 years are eligible
  3. History of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism).
  4. ≥ two of the following risk factors: Factor V Leiden, hormone replacement therapy, systemic containing estrogen, smoking, diabetes, hypercholesterolemia, medications for hypertension or cancer.
  5. Pre-existing cardiac disease (including congestive heart failure, and arrhythmia requiring treatment), or clinically significant findings on resting 12-lead at screening.
  6. Female subjects who are nursing or pregnant (positive serum or urine β-human chorionic gonadotrophin (β-hCG) pregnancy test) at screening or pre-dose on Day 1.
  7. History of alcohol/drug abuse.
  8. Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Single Arm

    Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone

    Drug: Eltrombopag

Interventions

  • Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone

06

What researchers measure

Primary outcomes

  1. The prolonged response rate

    Defined as proportion of patients with platelet counts \> 50,000/μl at 6 months after completion of therapy and free of ITP rescue therapy

    Time frame: 6 months after completion of therapy

Secondary outcomes

  1. Time to relapse

    Defined as the interval from completion of 3 months treatment to platelet count\<30,000/ul and restarting of ITP therapy including but not limited to platelet transfusion, IVIG, corticosteroids, immunosuppressive drugs, rituximab

    Time frame: 6 months after completion of therapy

  2. Early response rate

    Defined as proportion of patients requiring less than 3 courses of pulsed dexamethasone to maintain platelet counts \> 150,000/ul

    Time frame: 6 months after completion of therapy

  3. Health related quality of life

    Assessed by SV36 HRQoL questionnaires

    Time frame: 6 months after completion of therapy

07

Study locations

1 site
  • Humanity & Health Research Centre
    Hong Kong, Hong Kong SAR, Hong Kong
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2022, 53 months.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2019
First posted
Feb 5, 2019
StartActual
Jul 1, 2018
Primary completionActual
Dec 31, 2022
CompletionActual
Mar 31, 2023
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03830749
Lead sponsor
Humanity & Health Medical Group Limited
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Jul 1, 2018
Primary completion
Dec 31, 2022
Completion
Mar 31, 2023
Last update
Feb 28, 2024

Study contacts

Gregory Cheng, PhD, MD
principal investigator · Humanity & Health Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion